UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Journal of medicinal chemistry, 2015-08, Vol.58 (16), p.6348-6358

2015

Link zum Volltext

Verfügbarkeit prüfen

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201

Cancer research (Chicago, Ill.), 2018-11, Vol.78 (21), p.6257-6267

2018

Link zum Volltext

Verfügbarkeit prüfen

The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation

Cell, 2005-03, Vol.120 (6), p.747-759

2005

Link zum Volltext

Verfügbarkeit prüfen

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

The Journal of pharmacology and experimental therapeutics, 2002-09, Vol.302 (3), p.1055

2002

Link zum Volltext

Verfügbarkeit prüfen

In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase

Cancer cell, 2004-03, Vol.5 (3), p.231-239

2004

Link zum Volltext

Verfügbarkeit prüfen

Quantified Tumor T1 Is a Generic Early-Response Imaging Biomarker for Chemotherapy Reflecting Cell Viability

Clinical cancer research, 2010-01, Vol.16 (1), p.212-225

2010

Link zum Volltext

Verfügbarkeit prüfen

Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800

Molecular cancer therapeutics, 2010-04, Vol.9 (4), p.906-919

2010

Link zum Volltext

Verfügbarkeit prüfen

Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

Bioorganic & medicinal chemistry letters, 2016-10, Vol.26 (19), p.4837-4841

2016

Link zum Volltext

Verfügbarkeit prüfen

Protein Kinase C-mediated Phosphorylation Does Not Regulate Drug Transport by the Human Multidrug Resistance P-glycoprotein

The Journal of biological chemistry, 1996-06, Vol.271 (23), p.13668-13674

1996

Link zum Volltext

Verfügbarkeit prüfen

Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53–MDM2 interaction with a distinct binding mode

Bioorganic & medicinal chemistry letters, 2015-09, Vol.25 (17), p.3621-3625

2015

Link zum Volltext

Verfügbarkeit prüfen

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor

Bioorganic & medicinal chemistry letters, 2018-11, Vol.28 (20), p.3404-3408

2018

Link zum Volltext

Verfügbarkeit prüfen

Phosphatidylcholine translocase: A physiological role for the mdr2 gene

Cell, 1994-07, Vol.77 (7), p.1071-1081

1994

Link zum Volltext

Verfügbarkeit prüfen

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805

Molecular cancer therapeutics, 2010-07, Vol.9 (7), p.1945-1955

2010

Link zum Volltext

Verfügbarkeit prüfen

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

Pharmacology & therapeutics (Oxford), 2002-02, Vol.93 (2), p.79-98

2002

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4855: Discovery of NVP-HDM201 - First disclosure of a Next-Generation Mdm2 inhibitor with superior characteristics

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4855-4855

2016

Link zum Volltext

Verfügbarkeit prüfen

Discovery, X-ray structure and CPP-conjugation enabled uptake of / macrocyclic peptide inhibitors

RSC chemical biology, 2021-12, Vol.2 (6), p.1661-1668

2021

Link zum Volltext

Verfügbarkeit prüfen

Discovery, X-ray structure and CPP-conjugation enabled uptake of p53/MDM2 macrocyclic peptide inhibitors

RSC chemical biology, 2021-12, Vol.2 (6), p.1661-1668

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1225: NVP-HDM201: cellular and in vivo profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1225-1225

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract DDT01-01: Discovery of CGM097 as a novel Mdm2 inhibitor

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.DDT01-01-DDT01-01

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2909: A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2909-2909

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1797-1797

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(53)

Publikationsform

Sprache

Englisch
(53)
Japanisch
(11)
Deutsch
(4)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201

The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation

A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase

Quantified Tumor T1 Is a Generic Early-Response Imaging Biomarker for Chemotherapy Reflecting Cell Viability

Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800

Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097

A double blinded, placebo-controlled pilot study to examine reduction of CD34+/CD117+/CD133+ lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma

A double blinded, placebo-controlled pilot study to examine reduction of CD34 +/CD117 +/CD133 + lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma [version 3; peer review: 2 approved]

Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

Protein Kinase C-mediated Phosphorylation Does Not Regulate Drug Transport by the Human Multidrug Resistance P-glycoprotein

Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53–MDM2 interaction with a distinct binding mode

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor

Phosphatidylcholine translocase: A physiological role for the mdr2 gene

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

Abstract 4855: Discovery of NVP-HDM201 - First disclosure of a Next-Generation Mdm2 inhibitor with superior characteristics

Discovery, X-ray structure and CPP-conjugation enabled uptake of / macrocyclic peptide inhibitors

Discovery, X-ray structure and CPP-conjugation enabled uptake of p53/MDM2 macrocyclic peptide inhibitors

Abstract 1225: NVP-HDM201: cellular and in vivo profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2

Abstract DDT01-01: Discovery of CGM097 as a novel Mdm2 inhibitor

Abstract 2909: A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models

Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial

Suchergebnisse filtern